DNA Vaccine Scaffold Boosts HIV Immunity, Shows Promise for Difficult Vaccines

Developing an effective vaccine against HIV has long been hampered by the body’s complex immune response to the virus. A key challenge lies in stimulating the production of broadly neutralizing antibodies – those capable of targeting multiple strains of HIV, which rapidly mutates to evade the immune system. Now, researchers at Scripps Research and the Massachusetts Institute of Technology (MIT) have unveiled a novel vaccine scaffolding made from DNA that appears to overcome a significant hurdle: eliciting an immune response *against* the vaccine itself, diverting resources from a targeted attack on the virus.

Traditionally, vaccines present viral proteins attached to a larger protein scaffold, mimicking the structure of the virus to trigger an immune response. However, the immune system often recognizes and reacts to the scaffold itself, producing antibodies that neutralize it rather than focusing on the viral proteins. This “off-target” response can diminish the effectiveness of the vaccine, particularly for challenging pathogens like HIV, influenza, and emerging coronaviruses where generating broadly protective antibodies is exceptionally difficult.

The new approach, detailed in a February 5, 2026 publication in Science, utilizes DNA origami technology to create a scaffolding that the immune system largely ignores. “It’s a brand-new technology that might help us get to a protective HIV vaccine or solve other particularly difficult vaccine problems,” says Darrell Irvine, professor at Scripps Research and senior author of the study.

DNA origami allows scientists to fold DNA into precise three-dimensional shapes. Crucially, the researchers leveraged the fact that B cells – the immune cells responsible for producing antibodies – generally do not recognize and react to DNA, a natural protective mechanism to prevent autoimmune attacks on the body’s own genetic material. This “invisibility” of the DNA scaffold is the key innovation.

“We knew that protein nanoparticle scaffolds generate their own immune responses, but we didn’t know how much those off-target responses were actually limiting the immune cells we care about,” explains Irvine, who is also a Howard Hughes Medical Institute Investigator.

The team designed DNA nanoparticles capable of displaying 60 copies of an HIV envelope protein, a target known to activate the rare B cells that produce broadly neutralizing antibodies. Testing in mice engineered to express human antibody genes revealed a striking difference compared to vaccines using protein-based scaffolds. Nearly 60% of the germinal center B cells – specialized immune cells that mature into antibody-producing cells – targeted the HIV envelope protein when using the DNA scaffold. In contrast, the protein-scaffolded vaccine, currently undergoing clinical trials, generated germinal centers where only about 20% of B cells recognized the HIV target, with the remainder reacting to the scaffold itself.

The DNA-based vaccine demonstrated a 25-fold improvement in the ratio of HIV-specific to off-target immune cells. Within just two weeks of vaccination, mice receiving the DNA-based vaccine showed detectable levels of the desired rare B cells, while those receiving the protein nanoparticle-based vaccine showed none.

This enhanced focus on the viral target is particularly significant for pathogens like HIV, where broadly neutralizing antibodies are rare and difficult to elicit. The researchers emphasize that the implications extend beyond HIV, potentially offering a solution for developing vaccines against influenza and even pan-coronavirus vaccines – all of which face similar challenges in stimulating the right kind of immune response.

“These are vaccines where you’re trying to recruit incredibly rare cells in the B-cell repertoire,” Irvine adds. “Anything that limits those correct cells from getting activated is a potential problem, and DNA origami scaffolds could help overcome these challenges.”

The research teams, led by Irvine and Mark Bathe of MIT, are now investigating how variations in the shape of the DNA origami might further enhance vaccine effectiveness. They are also conducting studies to assess the long-term safety of the DNA scaffolds for vaccination purposes. Anna Romanov, lead author of the study, and collaborators at both institutions contributed to this breakthrough.

Prior research in 2024, utilizing a SARS-CoV-2 antigen, had already indicated that DNA scaffolds were immunologically “silent,” not triggering an antibody response. However, it remained unclear whether they could also promote the focused germinal center responses necessary for effective antibody production. This new study confirms that the DNA scaffold not only avoids unwanted immune reactions but actively enhances the development of the desired immune response against HIV.